A next-gen Ozempic falls short in a drug trial — and Novo Nordisk …

Dec 20, 2024 · Novo Nordisk reported that 40.4% of patients taking CagriSema achieved a weight loss of 25% or more over the 68-week trial period. The company is expected to reveal results …

CouponFollow Extension

4%
OFF

A Next-gen Ozempic Falls Short In A Drug Trial — And Novo Nordisk …

1 week from now

Dec 20, 2024 · Novo Nordisk reported that 40.4% of patients taking CagriSema achieved a weight loss of 25% or more over the 68-week trial period. The company is expected to reveal results …

yahoo.com

$94
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

1 week from now

Ozempic and Wegovy maker lost $94.5 billion in market value after releasing study results for a next-generation weight-loss drug. ... Novo Nordisk Shares Plunge After New Obesity Shot …

wsj.com

19%
OFF

Novo Nordisk Sinks On Disappointing Trial Results For Next Gen …

1 week from now

Dec 20, 2024 · Novo Nordisk's U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current …

investopedia.com

25%
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short Of ...

1 week from now

Dec 20, 2024 · The outcome falls short of the 25% weight loss Novo Nordisk had expected and dents its chances of becoming the company's next blockbuster drug after Ozempic and Wegovy.

morningstar.com

4%
OFF

Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing …

1 week from now

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing pressures and competition for its blockbuster semaglutide …

msn.com

43%
OFF

A Next-gen Ozempic Falls Short In A Drug Trial — And Novo Nordisk …

1 week from now

Novo Nordisk (NVO-17.43%) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street disappointed. Microsoft and Gretel team up to drive …

newsbreak.com

4%
OFF

Novo Nordisk Falls Most On Record After New Weight Drug …

1 week from now

Dec 20, 2024 · The shot helped patients lose an average of 20.4% of their weight over 68 weeks, short of the 25% weight loss that Novo had predicted for its next-generation product, which …

moneycontrol.com

21%
OFF

Novo Nordisk Drops After Ozempic Selected For U.S. Price …

1 week from now

2 days ago · Ozempic, Xtandi among next 15 drugs selected for U.S. price talks Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial Novo Nordisk price target …

businessinsider.com

21%
OFF

Ozempic Maker Novo Nordisk, After Trial Disappointment, Expands …

1 week from now

Jan 8, 2025 · Novo Nordisk shares plunged 21% in late December when the company said its CagriSema drug, in a late-stage trial, results in 20.4% weight loss, a figure which came in …

morningstar.com

$2
OFF

Ozempic Maker Novo Nordisk, After Trial Disappointment, Expands …

1 week from now

Jan 8, 2025 · Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been …

marketwatch.com

FAQs about A next-gen Ozempic falls short in a drug trial — and Novo Nordisk … Coupon?

Will Novo Nordisk's Ozempic successor be a diabetes drug?

Novo Nordisk (NVO) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street disappointed. The pharma giant, known for its blockbuster diabetes drug Ozempic, said its experimental diabetes and weight-loss drug CagriSema fell short of expectations. ...

Why did Novo Nordisk stock fall 21%?

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's stock plunged 21% to trade at $82.03 per share shortly after the opening bell on Friday morning, hitting its lowest level in over a year. ...

Why did Novo Nordisk stock sank 19% in premarket trading?

Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy. ...

Why did Novo Nordisk's shares tumble 19% Friday morning?

Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg. ...

Why did Novo Nordisk stock tank?

At a Novo Nordisk manufacturing plant in north China's Tianjin. Li Ran/Xinhua via Getty Images Novo Nordisk's stock tanked after a highly anticipated drug trial disappointed. The study showed its new obesity drug helped people lose less weight than expected. Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. ...

Does Novo Nordisk have a weight loss pill?

Danish pharma giant Novo Nordisk teased promising early-stage trial results of its experimental weight loss pill amycretin last week, resulting in the company’s stock surging. On Mar. 7, the company told investors that a small trial of the pill found that it could be twice as effective as the company’s current blockbuster weight loss drug. ...